A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn’s disease: an analysis of two propensity score-matched cohorts
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2022.2041082
Abstract: Abstract Background/aims Originator-adalimumab, an established treatment for patients with Crohn’s disease (CD), showed no difference in efficacy or adverse events versus adalimumab biosimilar SB5 (SB5-adalimumab) over 10 weeks (W) of treatment. To understand the long-term… read more here.
Keywords: sb5; treatment; originator adalimumab; sb5 adalimumab ... See more keywords
Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience
Sign Up to like & getrecommendations! Published in 2021 at "Asia-Pacific Journal of Ophthalmology"
DOI: 10.1097/apo.0000000000000380
Abstract: Purpose: Several concerns have arisen with biosimilars in terms of immunogenicity, safety issues, loss of efficacy, and extrapolation to other indications. The study aim was to evaluate the efficacy of SB5, an adalimumab biosimilar, in… read more here.
Keywords: last follow; noninfectious uveitis; uveitis relapses; sb5 ... See more keywords
SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.13435
Abstract: Dear Editor, Biosimilar therapies are an emerging option in the treatment of psoriasis and other immune-mediated diseases due to the lower impact on public health costs. SB5, commercially known as Imraldi (Samsung Bioepsis), is approved… read more here.
Keywords: treatment; treatment psoriasis; sb5 adalimumab; psoriasis ... See more keywords